Trials / Conditions / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
3 registered clinical trials studyying Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT NCT03435952 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer NCT03258008 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Lenvatinib and Capecitabine in Patients With Advanced Malignancies NCT02915172 | M.D. Anderson Cancer Center | Phase 1 |